Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – today announce the sale of Zentiva by Advent to GTCR.
At Zentiva, we provide health and wellbeing
for all generations
News from Zentiva
-
11. September 2025 / 2025
-
11. July 2025 / 2025
Zentiva is proud to announce a significant step forward in its sustainability strategy with official validation of its targets by the Science Based Targets initiative (SBTi). By setting near term and long-term net-zero Green House Gas (GHG) reduction targets in line with the SBTi, this commitment reinforces Zentiva’s dedication to sustainability and aligns our decarbonisation roadmap with the European Union’s goal of becoming the first climate-neutral continent by 2050.
-
9. July 2025 / 2025
Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin’s biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.
-
30. May 2025 / 2025
At Zentiva, we believe that each of us can contribute to taking care of our planet and doing what we can to protect it so that future generations can enjoy life as much as we do.
-
21. May 2025 / 2025
Zentiva supported Euractiv’s Health Policy Conference in Brussels, where its CEO, Steffen Saltofte, joined senior EU policymakers in the opening panel titled “The EU Pharmaceutical Legislation – Ensuring Fair Access to Medicines for All.”
-
9. April 2025 / 2025
For the fourth consecutive year, Zentiva is publishing its Sustainability Report, highlighting the key achievements delivered in 2024.
-
11. September 2025 / 2025
Zentiva, a leading European generics pharmaceutical company, Advent and GTCR – two leading global private equity investors – today announce the sale of Zentiva by Advent to GTCR.
-
11. July 2025 / 2025
Zentiva is proud to announce a significant step forward in its sustainability strategy with official validation of its targets by the Science Based Targets initiative (SBTi). By setting near term and long-term net-zero Green House Gas (GHG) reduction targets in line with the SBTi, this commitment reinforces Zentiva’s dedication to sustainability and aligns our decarbonisation roadmap with the European Union’s goal of becoming the first climate-neutral continent by 2050.
-
9. July 2025 / 2025
Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for commercialization of Lupin’s biosimilar, TNF alpha inhibitor medicine, across multiple markets globally.
-
30. May 2025 / 2025
At Zentiva, we believe that each of us can contribute to taking care of our planet and doing what we can to protect it so that future generations can enjoy life as much as we do.
-
21. May 2025 / 2025
Zentiva supported Euractiv’s Health Policy Conference in Brussels, where its CEO, Steffen Saltofte, joined senior EU policymakers in the opening panel titled “The EU Pharmaceutical Legislation – Ensuring Fair Access to Medicines for All.”
-
9. April 2025 / 2025
For the fourth consecutive year, Zentiva is publishing its Sustainability Report, highlighting the key achievements delivered in 2024.
-
17. December 2024 / 2024
Key takeaways included the emerging risk of medicine shortages. This not only contradicts the solidarity principle of the European Union but also burdens the industry with added costs and administrative demands.
-
9. December 2024 / 2024
-
18. November 2024 / 2024
-
12. November 2024 / 2024
We are proud to announce that Zentiva has successfully achieved the SAP Customer Center of Expertise (CCoE) certification.
-
8. November 2024 / 2024
In this episode, you will learn about data from beehive colonies turned into smart insights, helping us determine the ecological impact humans have in a certain area. In a nutshell, this AI-driven project uses bees as our smart environmental sensors to achieve sustainability goals.
